Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy

SIMPLE SUMMARY: Immune checkpoint blockade targeting PD-1/PD-L1 has a promising therapeutic efficacy in different tumors, but a significant percentage of patients cannot benefit from this therapy due to primary and acquired resistance during treatment. This review summarizes the recent findings of P...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Yu, Adam, Abdalla, Zhao, Chen, Chen, Honglei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915065/
https://www.ncbi.nlm.nih.gov/pubmed/33562324
http://dx.doi.org/10.3390/cancers13040663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915065/
https://www.ncbi.nlm.nih.gov/pubmed/33562324
http://dx.doi.org/10.3390/cancers13040663

Ejemplares similares